ArticleCancer research2022

Inhibition of FGFR Reactivates IFNγ Signaling in Tumor Cells to Enhance the Combined Antitumor Activity of Lenvatinib with Anti-PD-1 Antibodies.

Yusuke Adachi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.